高等学校化学研究 ›› 2013, Vol. 29 ›› Issue (4): 730-734.doi: 10.1007/s40242-013-2505-0
ZHANG Lei1,3, ZHANG Shi-tao1,3, ZHANG Xiao-ping2, SUN Jing1,3, WANG Yong-sen1,3, LIU Yue-long1,3, XUE Miao-miao1,3, WANG Zhi1, XING Shu1,3, MA Jun-feng1,3, LI Wan-nan1,3, FU Xue-qi1,3
ZHANG Lei1,3, ZHANG Shi-tao1,3, ZHANG Xiao-ping2, SUN Jing1,3, WANG Yong-sen1,3, LIU Yue-long1,3, XUE Miao-miao1,3, WANG Zhi1, XING Shu1,3, MA Jun-feng1,3, LI Wan-nan1,3, FU Xue-qi1,3
摘要:
The protein tyrosine phosphatases(PTPs) comprise a family of enzymes that specifically dephosphorylate tyrosyl residues. Among them, SHP-1 has been regarded as one of the best validated intracellular tyrosine phosphatases. Downregulation of SHP-1 has shown remarkable efficacy in improving insulin sensitivity in vivo in insulin signaling pathway. In this study, we found the role of Candesartan cilexetil targeting at SHP-1. The results indicate that Candesartan cilexetil was a competitive inhibitor to SHP-1(IC50=85.6 μmol/L and Ki=24 μmol/L). We also found that Candesartan cilexetil was more sensitive towards SHP-1 compared with other PTPs. Through the consequence of Western blotting, it showed that Candesartan cilexetil can strengthen the level of tyrosine phosphorylation of several key cellular proteins[such as insulin receptor(IR), insulin receptor substrate(IRS) and ERK] in insulin signaling pathway in HepG2 cells and improve the insulin sensitivity through inhibiting the protein phosphorylation of SHP-1. These findings showed that Candesartan cilexetil might be an important inhibitor of SHP-1 and had a great application potential in the treatment of diabetes through inhibiting the level of SHP-1 in insulin signaling pathway.